The NHS COVID-19 App was introduced in the UK on 24 September. Many welcome its arrival as another step to contain the spread of COVID-19, while others are concerned about using the app for data and privacy reasons.
Helen explores the potential legal implications for life sciences companies banning people from using the app while at work.
Read the full article in the European Pharmaceutical Review
